The following tools and resources on special topics in psoriasis have been compiled to assist you in managing psoriasis in clinical practice.
IPC’s International Fellowship program provides young dermatologists and researchers interested in psoriasis full access to the knowledge of our network of experts and represents our commitment to cultivating expertise in the field.
The IPC Psoriasis Masterclass program is designed for early to mid-career dermatologists interested in improving their expertise in caring for psoriasis patients. The program is a robust 10-hour curriculum delivered by international and regional experts.
This CME-accredited activity is for US dermatology and primary care professionals who treat psoriasis, aiming to improve evidence-based use of systemic and biologic therapies aligned with current guidelines.
This course from the World Health Organization (WHO) Academy provides an overview of psoriasis epidemiology, clinical features and subtypes, diagnosis, and management, along with perspectives on living with the disease.
How familiar are you with the latest in psoriasis care? Take these quizzes to find out.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
